2024
Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S, Knauf F, Knight J, Lieske J, Lowther W, Moochhala S, Nazzal L, Tasian G, Whittamore J, Sas D. Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory. Kidney International Reports 2024, 9: 3083-3096. PMID: 39534212, PMCID: PMC11551133, DOI: 10.1016/j.ekir.2024.08.031.Peer-Reviewed Original Research
2020
Pathophysiology and Treatment of Enteric Hyperoxaluria
Witting C, Langman C, Assimos D, Baum M, Kausz A, Milliner D, Tasian G, Worcester E, Allain M, West M, Knauf F, Lieske J. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clinical Journal Of The American Society Of Nephrology 2020, 16: 487-495. PMID: 32900691, PMCID: PMC8011014, DOI: 10.2215/cjn.08000520.Peer-Reviewed Original ResearchConceptsEnteric hyperoxaluriaGastrointestinal disordersBariatric surgical proceduresCurrent therapeutic optionsAvailable treatment strategiesUrinary oxalate excretionKidney stone eventsLong-term efficacyKidney Health InitiativeNew therapeutic approachesComplicated obesityDietary modificationFat malabsorptionOxalate excretionTherapeutic optionsAdverse outcomesKidney failureStone eventsTreatment strategiesDietary oxalateSurgical proceduresTherapeutic approachesSevere casesHyperoxaluriaHealth initiatives
2016
Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion
Knauf F, Thomson RB, Heneghan JF, Jiang Z, Adebamiro A, Thomson CL, Barone C, Asplin JR, Egan ME, Alper SL, Aronson PS. Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion. Journal Of The American Society Of Nephrology 2016, 28: 242-249. PMID: 27313231, PMCID: PMC5198290, DOI: 10.1681/asn.2016030279.Peer-Reviewed Original ResearchConceptsIntestinal oxalate secretionWild-type miceCystic fibrosisIntestinal tissueOxalate secretionIncidence of hyperoxaluriaCalcium oxalate stone formationNet intestinal absorptionOxalate stone formationCoexpression of CFTRIntestinal transport processesWestern blot analysisOxalate absorptionMouse modelIntestinal absorptionGlucose absorptionUssing chambersStone formationFibrosisMiceSecretionReduced expressionCystic fibrosis transmembrane conductance regulator (CFTR) geneHyperoxaluriaPatients
2012
Sat1 is dispensable for active oxalate secretion in mouse duodenum
Ko N, Knauf F, Jiang Z, Markovich D, Aronson PS. Sat1 is dispensable for active oxalate secretion in mouse duodenum. American Journal Of Physiology - Cell Physiology 2012, 303: c52-c57. PMID: 22517357, PMCID: PMC3404526, DOI: 10.1152/ajpcell.00385.2011.Peer-Reviewed Original ResearchConceptsCalcium oxalate stonesMouse duodenumOxalate secretionOxalate stonesIntestinal oxalate secretionIntestinal oxalate transportSecretory fluxSAT1 expressionDisulfonic stilbene DIDSDuodenumTransporter 1SecretionMiceHyperoxalemiaBasolateral solutionHyperoxaluriaBasolateral transportersBicarbonate productionOxalate transportBasolateral membraneSAT1Apical membraneComplete removalMedium concentration